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BACKGROUND AND PURPOSE
Receptor activity-modifying proteins (RAMPs) define the pharmacology of the calcitonin receptor-like receptor (CLR). The
interactions of the different RAMPs with this class B GPCR yield high-affinity calcitonin gene-related peptide (CGRP) or
adrenomedullin (AM) receptors. However, the mechanism for this is unclear.
EXPERIMENTAL APPROACH
Guided by receptor models, we mutated residues in the N-terminal helix of CLR, RAMP2 and RAMP3 hypothesized to be
involved in peptide interactions. These were assayed for cAMP production with AM, AM2 and CGRP together with their cell
surface expression. Binding studies were also conducted for selected mutants.
KEY RESULTS
An important domain for peptide interactions on CLR from I32 to I52 was defined. Although I41 was universally important
for binding and receptor function, the role of other residues depended on both ligand and RAMP. Peptide binding to
CLR/RAMP3 involved a more restricted range of residues than that to CLR/RAMP1 or CLR/RAMP2. E101 of RAMP2 had a
major role in AM interactions, and F111/W84 of RAMP2/3 was important with each peptide.
CONCLUSIONS AND IMPLICATIONS
RAMP-dependent effects of CLR mutations suggest that the different RAMPs control accessibility of peptides to binding
residues situated on the CLR N-terminus. RAMP3 appears to alter the role of specific residues at the CLR-RAMP interface
compared with RAMP1 and RAMP2.
Abbreviations
AM, adrenomedullin; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; ECD, extracellular
N-terminal domain; RAMP, receptor activity-modifying protein
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Introduction
Adrenomedullin (AM) and AM2 (intermedin) are 52 and 47
amino acid peptides that are members of the calcitonin
peptide family (Poyner et al., 2002; Hong et al., 2012). This
family also includes calcitonin gene-related peptide (CGRP)
and amylin. AM is involved in the development of the lym-
phatic and blood vasculature (Hinson et al., 2000; Fritz-Six
et al., 2008; Ichikawa-Shindo et al., 2008). AM2 is a more
recently discovered member of the AM family (Roh et al.,
2004; Takei et al., 2004a,b) and, along with AM, has extensive
effects on the CVS including vasodilatation, cardioprotec-
tion, modulation of vascular tone and stimulation of angio-
genesis (Hinson et al., 2000; Fujisawa et al., 2004; Takei et al.,
2004a,b).
The AM1 and AM2 receptors are class B (secretin family)
GPCR (Poyner et al., 2002). However, they differ from many
of the other members of this class, as they are formed from
the obligate co-expression of the calcitonin receptor-like
receptor (CLR) and receptor activity-modifying proteins
(RAMP) 2 or 3 respectively. The CGRP receptor is formed of a
complex between CLR and RAMP1 (McLatchie et al., 1998).
AM and AM2 both activate AM1 and AM2 receptors, although
AM2 has a 10-fold lower potency than AM at the AM1 recep-
tor (Hong et al., 2012). CGRP also activates AM1 and AM2
receptors although with reduced potency compared to AM
(McLatchie et al., 1998).
Class B GPCRs consist of a seven transmembrane helical
region connected by extra- and intracellular loops; they are
characterized by a large extracellular N-terminal domain
(ECD). Although to date no full length, peptide-bound class
B GPCR structures have been solved, the recent structures
of the transmembrane domains of the glucagon- and
corticotropin-releasing hormone receptor have given us great
insight into the configuration of the transmembrane domain
(Hollenstein et al., 2013; Siu et al., 2013). However, neither of
these structures captures the native orientation of the ECD
with respect to the transmembrane bundle and extracellular
loops, although the modelling of the position of the ECD
using the glucagon receptor structure may give some indica-
tion of its relative orientation (Siu et al., 2013). Crystal struc-
tures of isolated ECDs including the glucagon-like peptide-1
receptor (Runge et al., 2008; Underwood et al., 2010),
parathyroid hormone (PTH) receptor (Pioszak and Xu,
2008), glucose-dependent insulinotropic polypeptide recep-
tor (Parthier et al., 2007) and the corticotropin-releasing
hormone receptors (Pioszak et al., 2008) are available. These
structures support the two-domain model of peptide ligand
binding (Hoare, 2005; Parthier et al., 2009). This model
proposes that the C-terminal of the peptide is captured
by the receptor ECD, which induces the formation of an
α-helix in the peptide, stabilized by hydrophobic interac-
tions with the receptor ECD. These receptor ECDs share
the common ‘secretin family recognition fold’ consisting of
two antiparallel β-sheets and an N-terminal α-helix stabilized
by three disulphide bonds. The C-termini of the peptides
bind in a common binding groove in the ECD composed of
the N-terminal helix, ECD loops 2, 4 and the C-terminal
region.
It has long been a challenge to understand how RAMPs
allow different peptide preferences. It has been suggested
that RAMPs do this by directly interacting with peptides,
by altering the conformation of CLR or a combination of
both. However, in attempts to identify the RAMP residues
involved very few candidates have been identified (Qi and
Hay, 2010). Thus far, in RAMP1 only W84 has a substantial
effect on CGRP interactions (Moore et al., 2010). Its equiva-
lent in RAMP2 (F111) has been implicated in AM binding,
as has E101 (Kusano et al., 2012). Mutagenesis studies
of RAMP1 and RAMP3 indicate that W74 and E74 (the
analogous residue in each protein to E101 of RAMP2) are
involved in AM selectivity (Hay et al., 2006a; Qi et al.,
2008).
The recently determined crystal structures of the CGRP
and AM1 receptor ECDs show that RAMPs interact with CLR
by making extensive contacts with its N-terminal α-helix.
Although no peptide is bound in any of these structures (ter
Haar et al., 2010; Kusano et al., 2012), it has been proposed
that due to the high structural similarity of the CLR ECD to
the ECD of the parathyroid hormone (PTH)1 receptor, the
peptide-binding groove may be in a similar position in CGRP
and AM1 receptors (Archbold et al., 2011). This is broadly
supported by alanine substitution experiments in the CGRP
receptor, indicating that CLR residues I32, G35, T37 and I41
in the N-terminal α-helix form a cluster involved in the
modification of CGRP interactions (Barwell et al., 2010). Fur-
thermore, in the AM1 receptor, W72, F92 and W121 of CLR
are thought to be involved in AM binding by virtue of the
structural similarity of the CLR ECD to other class B ECD
structures, which contain bound peptide (Kusano et al.,
2012). If this is the case, then most RAMP residues would not
be in a position to make major contacts with AM and CGRP,
consistent with the lack of residues identified by RAMP
mutagenesis. Interestingly, the structures reveal that RAMP2
is slightly rotated with respect to CLR, compared with RAMP1
(Kusano et al., 2012). This RAMP–CLR interaction could affect
the exact position of the peptide-binding groove of CLR. An
AM2 (CLR/RAMP3) receptor ECD structure is not available for
comparison.
Therefore, there is much evidence pointing towards the
notion that RAMP influences the orientation of key residues
along the N-terminal α-helix of CLR, although the current
ECD structures do not have sufficient resolution to provide
details of this. In turn, this could affect the affinity of dif-
ferent peptide ligands for the CGRP, AM1 and AM2 receptors.
In addition, the conserved aromatic residue at position
84/111 of the three RAMPs may also play a major role
in influencing the peptide-binding groove, given its posi-
tion in the crystal structures of the CGRP and AM1 receptor
ECD.
In order to clarify the role of the RAMPs in ligand binding
we compared the effect of mutating residues along the
N-terminal α-helix of CLR on different peptides in the pres-
ence of different RAMPs. We also mutated the RAMP2 and
RAMP3 residues implicated in influencing peptide interac-
tions. We observed striking RAMP-dependent effects on the
function of CLR mutants and confirm that the conserved
aromatic residue at position 84/111 of RAMP is also a key
determinant of peptide interactions. However, we conclude
that the RAMPs are particularly important in the control of
accessibility to a peptide-binding groove located at the inter-
face between CLR and the RAMP.
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Methods
Materials
Human AM (AM 1–52), rat AM (rAM) and human αCGRP
were from American Peptide (Sunnyvale, CA, USA). Human
AM2 (AM2-47) was from Bachem, Bubendorf, Switzerland.
Forskolin was from Tocris Bioscience (Wiltshire, UK). AlphaS-
creen cAMP assay kits and all reagents and plates were from
PerkinElmer (Boston, MA, USA).
Expression constructs and mutagenesis
Human CLR with an N-terminal haemagglutinin (HA)
epitope tag, human RAMP2 with an N-terminal FLAG epitope
tag (Qi et al., 2013) and untagged human RAMP3 were
mutated using a method based on the Quik Change II site-
directed mutagenesis kit (Stratagene, Cambridge, UK) as
described previously (Conner et al., 2005; Bailey and Hay,
2007). The HA-CLR mutants have previously been described
(Barwell et al., 2010).
Cell culture and transfection
Culture of Cos7 cells was performed as previously described
(Bailey and Hay, 2006). Cells were cultured in DMEM supple-
mented with 8% heat-inactivated FBS and 5% (v/v) penicillin/
streptomycin and kept in a 37°C humidified 95% air, 5% CO2
incubator. For cAMP assays, cells were seeded into 96-well
plates at a density of 15 000 cells per well (determined using a
Countess Counter™, Invitrogen, Carlsbad, CA, USA) 1 day
before transfection. Cells were transiently transfected using
polyethylenimine (PEI) as described previously (Bailey and
Hay, 2006) using a 1:1 ratio of CLR to RAMP. For radioligand
binding assays, cells were seeded into 24-well poly-D-lysine-
coated plates (BD Biosciences, San Jose, CA, USA) at a density
of 75 000 cells per well 1 day before transfection and trans-
fected using PEI; total amount used, 1 μg of DNA per well.
cAMP assay
cAMP assays were performed as previously described (Gingell
et al., 2010). Briefly, on the day of the assay, cells were serum-
deprived in DMEM containing 1 mM IBMX and 0.1% BSA for
30 min. Peptides, reconstituted to 1 mM in ultra-pure water,
were diluted in the same medium to give a final concentra-
tion range of 1 pM to 1 μM. Peptides were added to cells and
incubated at 37°C for 15 min. The contents of the wells were
then aspirated, and 50 μL of ice-cold absolute ethanol was
added and allowed to evaporate. cAMP was extracted by
adding 40 μL of lysis buffer, and the plates were gently shaken
at room temperature for 15 min. Ten microlitres of each cell
lysate was transferred to a 384 well plate, followed by 5 μL of
acceptor beads, and the plate was sealed and incubated in the
dark for 30 min at room temperature. Five microlitres of the
donor bead mix was added to all wells; the plate was resealed
and incubated in the dark for 16 h. The plates were read using
an Envision plate reader (PerkinElmer). The quantity of cAMP
produced was determined from the raw data using the cAMP
standard curve.
Radioiodination and radioligand binding
rAM was iodinated using iodobeads (Pierce, Rockford, IL,
USA). One iodobead was incubated with 100 μg (20 nmol)
rAM and 1 mCi Na125I (PerkinElmer) for 5 min at room tem-
perature. Iodinated rAM was purified by reverse phase HPLC.
[125I]-rAM eluted as a single peak at 26% acetonitrile. Homolo-
gous competition radioligand binding assays were conducted
on Cos7 cells in 24-well plates. Cells were washed once with
warm-binding buffer (DMEM, 0.5% BSA). Wash media were
replaced with ice-cold binding buffer followed by binding
buffer containing [125I]-rAM (approximately 3 pmol, 30 000
cpm per well) and depending on experimental design increas-
ing concentrations of unlabelled peptide. These ranged from
3 μM (non-specific binding) to 10 pM for human AM (hAM)
and 10 μM to 10 nM for hAM2 and hαCGRP; each concen-
tration was in duplicate or triplicate. Total binding was
assessed in the absence of unlabelled peptide. Cells were then
incubated at 4°C for 1 h followed by one wash with ice-cold
PBS, pH 7.4 and solubilized in 0.2 M NaOH. Radioactivity was
determined using a Wizard2 gamma counter (PerkinElmer).
Analysis of cell surface expression of mutants
by ELISA
Cell surface expression of all RAMP/HA-CLR receptor com-
plexes was assessed by measuring HA-CLR expression in an
ELISA as previously described (Bailey and Hay, 2007). For
selected mutants, FLAG-RAMP2 expression was also meas-
ured. Values were normalized to wild-type (WT) RAMP/CLR
as 100% and empty vector transfected cells as 0%. In most
assays, HA-CLR expression was used for normalization pur-
poses, except in assays specifically measuring FLAG-RAMP2.
Statistical significance between WT and mutants was deter-
mined by the Kruskal–Wallis test followed by a post hoc
Dunn’s test.
Generation of an AM2 receptor ECD model
Previously reviewed RAMP1 and RAMP3 full-length
sequences were downloaded from the UniProt server, and a
multiple sequence alignment was generated using the
T-Coffee server (Poirot et al., 2003). Modeller9v8 (Sali and
Blundell, 1993; Fiser and Sali, 2003) was used to generate 500
models of CLR/RAMP3 ECD using chains A and D from the
protein database (PDB) accession 3N7S as templates. RAMP3
had a standard N-terminus cap whereas CLR contained an
acetylated N-terminus. Both RAMP3 and CLR contained
N-methylamide C-termini. This modification prevents
unnecessary large electrostatic attractive forces between the
ends of the protein fragment during energy minimization.
The models were ranked by the Modeller9v8 energy objective
function. The top 10 structures were retained, and the stereo-
chemical quality was assessed by PROCHECK v3.5.4
(Laskowski et al., 1993; Laskowski, 2001). Based on overall
and residue-by-residue geometry a structure was selected. The
ProPka programme (Li et al., 2005) via the PDBQPR server (see
Dolinsky et al., 2007) was used to assign the protonation
states of the titratable groups in CLR ECD, using the Chem-
istry at HARvard Molecular Mechanics (CHARMM) param-
eters set at pH 7.0. The CHARMM (c35b3) module Screened
Coulomb Potentials Implicit Solvent Model was used to mini-
mize the model. One hundred steps of steepest descent were
conducted followed by adopted basis Newton–Raphson mini-
mization until convergence was met.
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Data analysis
Data analysis was performed in GraphPad Prism 6 (GraphPad
Software Inc., San Diego, CA, USA). Data were fitted to obtain
concentration–response curves using a four parameter logis-
tic equation, and an F-test was conducted to compare
whether the Hill slope of the curves was significantly differ-
ent from 1. In most analyses, the Hill slope was not different
from 1 and was therefore constrained to 1. From these curves,
pEC50 values were obtained. Data were normalized in each
experiment to the fitted minimum and maximum of the WT
curve on each assay plate. Emax values from these curves are
reported. The means of replicates from these individual
experiments were combined to generate the curves that are
shown. pEC50 and Emax values are presented as the mean ±
SEM of values from individual data sets and were tested for
statistical significance versus WT using a paired t-test. For
radioligand binding assays specific binding was calculated by
subtraction of non-specific binding (the highest unlabelled
hAM concentration). Binding curves were analysed as for
cAMP assays and normalized to their fitted minimum and
maximum. pIC50 values from these curves are reported and
tested for statistical significance using an unpaired t-test.
Curves are presented as the combined means of data from
each unlabelled hAM concentration for each individual
experimental repeat. For the determination of relative
binding for each of the mutant receptors compared with WT,
specific binding data were normalized to the mean of specific
binding for the WT receptor and an overall mean value cal-
culated and analysed for statistical significance using the
Kruskal–Wallis test followed by a post hoc Dunn’s test. For all
assays, significance was accepted at P < 0.05.
Results
Selection of residues in CLR, RAMP2
and RAMP3
We used the CGRP and AM1 receptor structures along with
the residues involved in CGRP binding at the CGRP receptor
to guide this study of residues potentially involved in
peptide–receptor interactions (Barwell et al., 2010; ter Haar
et al., 2010; Kusano et al., 2012). Residues along the exposed
face of the CLR ECD helix ranging from V36 to I41 were
selected for alanine substitution. We also focused on a region
of importance in the CGRP receptor N-terminal to this helix
and beyond the extent of the crystal structures between resi-
dues I32 and G35. Proceeding further along the same face of
the ECD helix as I41, we did not test C48 as this forms a
disulphide bond with C74, which is integral to the structural
integrity of the ECD. Y49 is predicted to form part of the
RAMP2/CLR interface (ter Haar et al., 2010; Kusano et al.,
2012). We therefore tested this for cell surface expression. To
further refine the limits of the binding pocket, the next
residue whose effect we tested along the ECD helix was I52.
We also tested two RAMP2 residues that are in the vicinity of
I41 (E101, F111) and the corresponding RAMP3 residue
(W84). Mutant receptors were assayed for cAMP production
at the AM1, AM2 and CGRP receptors when stimulated with
hAM or hAM2. The AM2 receptor was also stimulated with
hαCGRP. hαCGRP was not used to stimulate the AM1 receptor
due to its very low binding affinity and potency at this recep-
tor (McLatchie et al., 1998; Aiyar et al., 2001; Poyner et al.,
2002).
Residues in the CLR ECD in the AM1 receptor
– stimulation of cAMP production
At the AM1 receptor the point mutants I32A, Q33A, G35A and
V36A had no effect on AM potency (Table 1). L34A, T37A,
I41A, M42A, Q45A and I52A all showed a decrease in AM
potency, although the effect of T37A was not statistically
significant (Table 1; Figure 1). I41A had the largest effect.
AM2 potency at the AM1 receptor was affected in a similar
manner to AM; however, in this case very large reductions in
potency were seen for T37A, I41A and Q45A. No change was
seen in AM2 potency for I52A, and a small reduction in
potency was observed for G35A. Emax was substantially
decreased for I41A and Q45A when the AM1 receptor was
stimulated with AM and AM2. The Emax for Q33A with both
ligands was substantially increased. Emax data are also pre-
sented in Supporting Information Figure S1 for easy compari-
son between receptors and peptides.
Residues in the CLR ECD in the AM2 receptor
– stimulation of cAMP production
At the AM2 receptor I32A, Q33A, V36A, M42A, Q45A and
I52A had no effect on the potency of AM, AM2 or hαCGRP
(Table 2). L34A and G35A decreased AM potency. T37A and
I41A had a substantial effect on AM and AM2 potency. Only
T37A and I41A had major effects on hαCGRP, with large
reductions in Emax (Table 2, Figure 2). No significant effects on
Emax were observed with any ligand for Q33A and Q45A.
Residues in the CLR ECD in the CGRP
receptor – stimulation of cAMP production
A similar study has been carried out to assess the effects of
these mutations on CGRP potency at the CGRP receptor
(Barwell et al., 2010). To provide an accurate comparison with
all three RAMPs, we additionally studied the effects of
selected mutations on AM and AM2 in the CGRP receptor. For
AM, only I41A affected potency and only Q45A affected Emax
(Table 3; Figure 3). More effects were seen with AM2; G35A,
T37A, I41A and Q45A all showed a decrease in potency. Emax
values were also decreased for I41A and Q45A. The Emax was
increased for AM2 at the I32A CGRP receptor.
Residues in the RAMP2 ECD in the AM1
receptor – stimulation of cAMP production
E101A and F111A mutations in RAMP2 both substantially
affected receptor function (Table 4; Figure 4). For E101A this
was evident as a 20-fold reduction in AM potency. With
F111A, potency was apparently preserved but there was a
large reduction in Emax. Due to the low Emax, the potency
estimate should be treated with caution. Both residues
also affected AM2-mediated receptor activation in a similar
fashion.
Residues in the RAMP3 ECD in the AM2
receptor – stimulation of cAMP production
We have previously extensively characterized mutations at
E74 of RAMP3, the equivalent to E101 in RAMP2 (Hay et al.,
BJPCGRP and AM-binding residues
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2006b; Qi et al., 2008). The RAMP3 equivalent to F111 is
W84. W84A resulted in a large decrease in AM potency and
Emax, a smaller decrease in AM2 potency but a large decrease
in Emax and complete abolition of hαCGRP responses (Table 4;
Figure 5). The conservative mutation of W84F partially
restored receptor function, with less perturbation of potency
and Emax. AM potency was reduced only threefold with this
mutation, and AM2 potency was not significantly reduced.
hαCGRP responses were measurable with this mutation. A
summary of all cAMP data is presented in Figure 6.
Residues in the CLR ECD in the AM1 and
AM2 receptors – ligand binding
We used a whole-cell 125IrAM binding assay to determine the
relative affinities of AM, AM2 and hαCGRP at the AM1 recep-
tor. hAM had a mean pIC50 of 8.29 ± 0.25 (n = 4) and hαCGRP
showed very weak binding (Figure 7), consistent with litera-
ture reports (Aiyar et al., 2001). hAM2 showed a 10-fold lower
pIC50 than hAM (7.25 ± 0.05, n = 4, P < 0.01 by unpaired
t-test), consistent with their rank order of potency (Hong
et al., 2012).
Our cAMP assays indicated some differences in the role of
CLR ECD residues between the AM1 and AM2 receptors. To
further investigate this, we performed radioligand binding
assays on selected mutants. Specific binding was abolished at
both receptors for T37A and I41A (Figure 7). Binding was also
abolished at the AM1 receptor with M42A and Q45A. Inter-
estingly, specific binding was retained for both of these
mutants at the AM2 receptor, in line with the cAMP data.
Given that Q45A also showed a large differential effect in
cAMP assays, we determined the pIC50 for AM at the AM2
receptor. This was 7.51 ± 0.21 (n = 3). The WT pIC50 was 7.69
± 0.11 (n = 3); there was no significant difference between
these values. Only 152A retained binding at the AM1 receptor
and full-curve analysis showed no difference in pIC50 for AM
compared with WT [8.02 ± 0.03 (n = 3) for I52A vs. 8.29 ± 0.25
(n = 4) for WT].
Cell surface expression
The CLR and RAMP2 or RAMP3 components are individually
expressed inefficiently at the cell surface (McLatchie et al.,
1998); however, when either RAMP2 or RAMP3 is expressed
together with CLR, they are translocated to the cell surface to
form functional AM1 or AM2 receptors respectively. The pres-
ence of HA-CLR at the cell surface can therefore be used as an
estimate of AM receptor complex expression. To determine
whether a change in binding or peptide responsiveness with
the mutations was due to perturbed cell surface expression,
we performed whole-cell ELISAs. For almost all mutants, the
mean expression was within 50% of WT and any reduction
was not statistically significant (Table 5). Previously, we have
shown that reductions of less than 50% in cell surface expres-
sion in our Cos7 cells do not substantially perturb cAMP
responsiveness (Bailey and Hay, 2007). Only Y49A at the AM1
receptor and W84A RAMP3 in the AM2 receptor (Table 5)
caused a significant reduction in HA-CLR expression. As
Q45A and Y49A are found at the interface between CLR and
RAMP2, we additionally tested FLAG-RAMP2 expression for
these two mutants to determine whether any reduction in
CLR expression was likely to be caused by a disruption in
CLR/RAMP2 complex formation. The results were consistent
with the HA-CLR measurements with FLAG-RAMP2 expres-
sion only significantly reduced with the Y49A mutation (13.1
± 12.5%, n = 4, P < 0.01 by Kruskal–Wallis test followed by
Dunn’s test) and reduced to a lesser degree with the Q45A
mutation (73.5 ± 10.7%, n = 3).
Table 1
Summary of pEC50 and Emax values for mutants of CLR in the AM1 receptor when stimulated with hAM or hAM2
hAM hAM2
WT Mutant Emax %WT n WT Mutant Emax %WT n
CLR I32A 9.07 ± 0.21 9.21 ± 0.27 133.9 ± 19.4 3 8.23 ± 0.03 8.24 ± 0.09 110.7 ± 15.5 3
CLR Q33A 9.06 ± 0.06 9.15 ± 0.05 269.4 ± 44.2* 4 8.12 ± 0.09 7.89 ± 0.12 281.0 ± 92.5 4
CLR L34A 8.89 ± 0.03 8.50 ± 0.09* 104.7 ± 42.9 3 8.25 ± 0.16 7.64 ± 0.20** 117.9 ± 17.9 4
CLR G35A 9.07 ± 0.22 8.91 ± 0.23 139.9 ± 26.8 3 8.22 ± 0.02 7.92 ± 0.03* 92.9 ± 3.07 3
CLR V36A 9.07 ± 0.22 8.92 ± 0.25 138.2 ± 19.8 3 8.22 ± 0.02 7.89 ± 0.18 153.9 ± 50.8 3
CLR T37A 8.94 ± 0.13 8.25 ± 0.19 89.0 ± 9.96 3 8.12 ± 0.26 6.99 ± 0.21 70.6 ± 12.1 2a
CLR I41A 9.14 ± 0.18 7.91 ± 0.34* 33.7 ± 2.37*** 4 8.21 ± 0.34 No curve 3
CLR M42A 9.11 ± 0.05 8.48 ± 0.08* 139.6 ± 36.9 3 8.21 ± 0.10 7.86 ± 0.13 89.9 ± 26.6 4
CLR Q45A 9.03 ± 0.19 8.45 ± 0.22*** 26.1 ± 8.61** 5 8.48 ± 0.24 No curve 3
CLR I52A 9.05 ± 0.16 8.66 ± 0.20* 136.1 ± 33.6 6 8.03 ± 0.17 8.11 ± 0.24 94.6 ± 9.00 3
Data are the mean ± SEM of n individual data sets.
*P < 0.05; **P < 0.01; ***P < 0.001 versus WT receptor by paired t-test.
aIn two other experiments, the mutant did not produce any measurable response. ‘No curve’ indicates that the mutation abolished
measurable receptor function.
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Figure 1
hAM and hAM2 stimulated cAMP responses of CLR mutant AM1 receptors. Normalized data were combined and data points shown are mean ±
SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.
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Discussion
The recently solved crystal structures of the AM1 and CGRP
receptor ECDs have greatly expanded our understanding of
these receptors and the interaction of their common CLR
subunit with these two different RAMPs. Of these, the CGRP
receptor ECD is the most complete, especially at the
N-terminus of CLR. However, the lack of bound peptides in
these structures gives us limited insight into the manner of
peptide binding to these receptors. Mutagenesis studies pin-
pointed the extreme N-terminus of CLR as a key determinant
of CGRP binding to the CGRP receptor ECD. We have now
defined an essential region for peptide binding in the three
CLR-based receptors (Figure 6; Supporting Information
Figure S1). This centres around I41 with contributions from
T37 and Q45, and lesser contributions from I32, Q33, L34,
G35, M42 and I52, depending on the RAMP co-expressed.
These residues mainly contribute to agonist binding and thus
potency, although, especially for I32 and Q33, there are
effects on Emax. We observed potentially important differences
in the function of CLR residues in the presence of RAMP3,
compared with RAMP1 and RAMP2.
The N-terminus of CLR is predominantly helical,
although the region N-terminal to T37 in the CGRP receptor
structure is somewhat disordered. In one of the three struc-
tures (3N7P) of the CGRP receptor ECD (3N7P, 3N7R and
3N7S), it is not helical and in all structures the atoms have
high b-factors, indicating significant mobility (ter Haar et al.,
2010; Barwell et al., 2012). These extreme N-terminal residues
lie beyond the extent of the AM1 receptor structure. Interest-
ingly, this region has very low-sequence identity across
species compared with the rest of the N-terminal region (Sup-
porting Information Figure S2), and the periodicity of these
residues implies that this region may not be helical. The
ability of I32 and Q33 to increase Emax may mean that these
residues are able to influence ligand binding to the trans-
membrane core or the conformation of CLR to promote cou-
pling to Gs, possibly via an interaction with one of the
extracellular loops of the receptor. However, without a full-
length (ligand-bound) receptor structure their steric relation-
ship to the transmembrane bundle and extracellular loops is
speculative.
T37, I41 and Q45 are highly conserved across species
(Supporting Information Figure S2), and each has interesting
effects upon mutation in the three CLR-based receptors.
These residues all lie on the same face of the N-terminal CLR
helix, and in the CGRP and AM1 receptor ECD crystal struc-
tures have their side chains projecting upwards into a groove
between CLR and the RAMP, in a good position to interact
with a ligand that might bind in this area.
I41 is universally important for cAMP accumulation and
binding; it has also been shown to be important for the
binding of CGRP to the CGRP receptor (Barwell et al., 2010).
The equivalent residue is important for glucagon binding to
the glucagon receptor (Siu et al., 2013). The hydrophobic side
chain of I41 is in an exposed position, at the entrance to the
interface between CLR and all three RAMPs (Figure 8). We
suggest that it acts as a pivot point for peptide binding and is
probably a direct contact for all three agonists.
Beyond I41, the accessibility of the residues on the CLR
helix sharply decreases (Figure 8), although the details of thisTa
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Figure 2
hAM, hAM2 and hαCGRP stimulated cAMP responses of CLR mutant AM2 receptors. Normalized data were combined and data points shown are
mean ± SEMof at least three individual data sets. Normalization is relative to the paired fittedmaximal and basal cAMPproduction of theWT receptor.
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are RAMP-dependent (ter Haar et al., 2010; Kusano et al.,
2012). The side chain of M42 is perpendicular to those of T37,
I41 and Q45 and points towards the RAMP. Although it is
sufficiently accessible to be important for the binding of
non-peptide antagonists to the CGRP receptor (ter Haar et al.,
2010; Miller et al., 2010), this change of angle is likely to
make it particularly inaccessible to any peptide orientated
parallel to the main axis of the CLR N-terminal helix. Its
effect on hAM binding and small effect on hAM potency in
the AM1 receptor may not therefore be due to a direct inter-
action with the peptide but to a localized disruption of the
structure of the AM-binding pocket.
The side chains of Q45 and Y49, although favourably
orientated for peptide binding, are also deep enough within
the CLR/RAMP interface to interact with conserved tyrosine
residues in RAMP1 and RAMP2. The effects of Y49 are par-
ticularly notable; mutation of this residue abolishes binding
and substantially reduces expression in the CGRP receptor
(Barwell et al., 2010). Similar effects on cell surface expression
are seen in the AM1 receptor. These data suggest that the main
effect of Y49 is to stabilize the CLR/RAMP interface in the
CGRP and AM1 receptors, rather than having a direct effect
on ligand binding. In contrast, the major effect of Q45A on
the AM1 receptor is most likely to be due to an effect on the
peptide-binding pocket, perhaps as a contact for AM. Like
Y49A, this residue shows intriguing differential behaviour in
the presence of RAMP3. This will be explored further below.
I52 is situated on the opposite face of the ECD to the
proposed peptide-binding cleft and is not readily accessible
to ligand, consistent with its very minor role in binding
and peptide responsiveness at each of the three receptors
(Barwell et al., 2010). The crystal structures of ligand-free or
antagonist-bound receptors in the absence of the transmem-
brane domains of either CLR or RAMP may of course not be
an accurate reflection of the agonist-bound state of the intact
receptors; in particular, there may be rearrangements to
increase accessibility of the binding groove in the CLR-RAMP
interface. Nonetheless, it is reasonable to assume that the
residues C-terminal to I41A will remain partly buried.
The proposed essential binding residues of the three
receptors are presented in Figure 8. The RAMP residue W84/
F111 is similarly involved in all of the binding pockets and is
conserved within each RAMP across a wide range of species
(Hay et al., 2006a). Interestingly, the W74/E101/E74 position
is only hydrophobic in RAMP1 where its mutation causes an
increase in AM and AM2 binding but has no effect on CGRP
binding (Figure 8) (Qi et al., 2008; Moore et al., 2010). The
conserved polar residue E101 (W74 in RAMP1) is not particu-
larly prominent, being situated further back in the AM1 recep-
tor binding pocket. However, it may still form the top of our
putative peptide-binding pocket as it does have a substantial
role to play in AM potency at the AM1 and AM2 receptors.
These effects correspond with the decrease in binding affinity
of AM to these mutants at the AM1 receptor ECD, as deter-
mined using surface plasmon resonance (Kusano et al., 2012).
Mutation of this position has fewer effects on AM2 potency at
both receptors (Qi et al., 2011). Taken together with the posi-
tion of all of these residues in the AM1 receptor ECD crystal
structure, the data collectively suggest that the CLR residues
from I41 and the RAMP2 residue F111 form a hydrophobic
area at the back of the peptide-binding groove. E101 forms a
polar sub-region of this area that may contribute to ligand
selectivity between the AM1, AM2 and CGRP receptors. A
similar hydrophobic region is formed by I41 and the corre-
sponding RAMP1 residues W74 and W84 in the CGRP recep-
tor crystal structure (ter Haar et al., 2010). Our data and
model of the AM2 receptor ECD suggest that the top of the
pocket may be formed in an analogous manner. There are a
number of hydrophobic regions in the C-terminal region of
CGRP, AM and AM2 that could dock in such an environment.
For example, the C-terminal amide residue of the three pep-
tides is a conserved aromatic residue (Tyr or Phe), which is
essential for the binding of AM22–52 and CGRP derivatives
(Watkins et al., 2012; 2013; Moad and Pioszak, 2013). The
Table 3
Summary of pEC50 and Emax values for mutants of CLR in the CGRP receptor when stimulated with hAM or hAM2
hAM hAM2
WT Mutant Emax %WT n WT Mutant Emax %WT n
CLR I32A 8.35 ± 0.14 8.33 ± 0.14 82.8 ± 16.5 4 8.42 ± 0.22 8.52 ± 0.33 141.9 ± 6.01* 3
CLR L34A 8.49 ± 0.25 8.64 ± 0.09 87.8 ± 6.35 3 8.51 ± 0.20 8.44 ± 0.10 358.9 ± 118.4 3
CLR G35A 8.41 ± 0.17 8.21 ± 0.14 112.1 ± 11.1 3 8.40 ± 0.20 8.04 ± 0.20* 149.8 ± 41.1 4
CLR V36A 8.22 ± 0.06 8.25 ± 0.08 124.3 ± 26.3 3 8.42 ± 0.22 8.21 ± 0.25 127.3 ± 19.8 3
CLR T37A 8.36 ± 0.27 8.09 ± 0.21 125.4 ± 20.6 3 8.31 ± 0.19 7.47 ± 0.26* 83.0 ± 15.2 3
CLR I41A 8.54 ± 0.16 7.47 ± 0.13* 68.4 ± 11.4 4 8.31 ± 0.19 7.23 ± 0.34* 57.4 ± 8.66* 3
CLR M42A 8.36 ± 0.27 8.25 ± 0.21 106.9 ± 26.8 3 8.33 ± 0.20 8.27 ± 0.20 92.5 ± 9.76 3
CLR Q45A 8.23 ± 0.25 7.87 ± 0.13 49.9 ± 4.27** 3 8.65 ± 0.07 7.97 ± 0.08* 34.7 ± 9.56* 3
Data are the mean ± SEM of n individual data sets.
*P < 0.05; **P < 0.01 versus WT receptor by paired t-test. To confirm cross-compatibility of assays, an experiment with CGRP under the same
assay conditions as for AM and AM2 gave values of 10.1 for the WT receptor and 9.09 for the I41A CGRP receptor, consistent with the findings
of Barwell et al. (2010).
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Figure 3
hAM and hAM2 stimulated cAMP responses of CLR mutant CGRP receptors. Normalized data were combined and data points shown are mean
± SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.
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aromatic side chain of this residue could form hydrophobic
interactions or pi–pi stacking in this area (Archbold et al.,
2011). Peptide binding to class B GPCRs ECDs involves the
formation of hydrophobic interactions that result in the for-
mation of an α-helix in the peptide ligand (Parthier et al.,
2009). The mutation of hydrophobic residues along the CLR
ECD helix and at the top of our proposed binding pocket
could therefore affect ligand structure as well as peptide
binding.
It is possible to comment on some general features of
RAMP action and their implications for peptide binding. A
greater number of residues in CLR investigated in this study
are involved in peptide interactions with RAMP1 and RAMP2,
compared with RAMP3 (Figure 6). This is particularly striking
for M42 and Q45, which do not influence peptide binding to
the AM2 receptor. We propose that RAMP3 either orientates
all three peptides at an angle so as to miss the main part of
the groove between it and CLR, or it changes the shape of the
groove. The latter proposition is supported by the differential
effect of Y49A on CLR cell surface expression with RAMP1,
RAMP2 and RAMP3. The reduction with RAMP1 and RAMP2
confirm that this is an important interface residue between
these RAMPs and CLR. However, the data strongly suggest
that Y49 may not assume the same role in CLR/RAMP3 com-
plexes. However, our CLR/RAMP3 ECD model cannot inform
us as to any possible differences in the interface between CLR
and RAMP3 compared with the other RAMPs, because it is aTa
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Table 5
Summary of cell surface expression data for HA-CLR in mutant AM1
and AM2 receptors
Mutant
AM1 receptor AM2 receptor
HA-CLR HA-CLR
%WT %WT
CLR I32A 83.1 ± 6.71 (3) 113.7 ± 25.8 (3)
CLR Q33A 115.8 ± 33.9 (3) 116.2 ± 14.2 (5)
CLR L34A 95.5 ± 7.54 (4) 107.2 ± 7.15 (3)
CLR G35A 90.8 ± 10.4 (3) 94.7 ± 8.95 (3)
CLR V36A 78.5 ± 8.74 (3) 96.9 ± 2.28 (3)
CLR T37A 80.5 ± 10.3 (3) 126.5 ± 12.5 (5)
CLR I41A 65.7 ± 9.52 (5) 86.4 ± 9.69 (3)
CLR M42A 123.7 ± 20.9 (3) 112.8 ± 19.4 (5)
CLR Q45A 61.5 ± 5.91 (3) 104.9 ± 12.8 (3)
CLR Y49A 25.9 ± 7.91 (4)** 111.6 ± 8.25 (4)
CLR I52A 98.7 ± 7.11 (3) 116.2 ± 19.5 (3)
RAMP2 E101A 98.78 ± 10.4 (4) –
RAMP2 F111A 95.79 ± 13.1 (4) –
RAMP3 W84A – 47.7 ± 4.67 (6)*
RAMP3 W84F – 63.6 ± 3.79 (4)
Data are the mean ± SEM of n individual data sets (in
parentheses).
*P < 0.05; **P < 0.01 versusWT receptor by the Kruskal–Wallis test
followed by Dunn’s multiple comparison test. –, not applicable.
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Figure 4
hAM and hAM2 stimulated cAMP responses of RAMP2 mutant AM1 receptors. Normalized data were combined and data points shown are mean
± SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.
Figure 5
hAM, hAM2 and hαCGRP stimulated cAMP responses of RAMP3 mutant AM2 receptors. Normalized data were combined and data points shown
are mean ± SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT
receptor.
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Figure 6
Effect of mutations in the N-terminal CLR residues on pEC50 values. Data are ordered to show the effect induced by RAMP (left) or peptide (right).
The ΔlogEC50 values were calculated by subtracting the mean pEC50 for a given ligand at a given mutation from the mean of its paired WT control.
For comparisons with the CGRP receptor, these values were calculated from the data presented in Barwell et al. (2010). Values above the line are
an increase in potency and below the line are a decrease. Where the mutation abolished measurable receptor function, an arbitrary value of two
has been assigned.
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homology model based on the CGRP receptor ECD structure.
A crystal structure of the CLR/RAMP3 ECD is needed to deter-
mine the specific position of residues at the interface between
these proteins. Nonetheless, the idea that the interface is
different between each CLR/RAMP complex is also supported
by mutation of the RAMP residue (W84/F111), which has
modest effects on cell surface expression with RAMP1 and
RAMP3 but not RAMP2 (Moore et al., 2010). This position
may have a dual role in ligand binding and stabilization of
the RAMP/CLR interface, depending on the RAMP.
In contrast to RAMP3, RAMP1 and RAMP2 support the
involvement of more N-terminal helix residues, suggesting
that the peptides lie parallel to these. CGRP and AM2 may sit
slightly further forward (to the N-terminus of the CLR helix)
than AM, depending on the RAMP. This is unlike the situa-
tion found for the majority of other class B GPCR ECDs that
do not require a RAMP. In these cases, the bound peptide is at
approximately 45° to the ECD helix, with the C-terminal
amide (where present in the structure) binding to a residue in
loop 4 of the receptor ECD, although the precise orientation
of the individual peptides differs (Pioszak and Xu, 2008;
Pioszak et al., 2009; Pal et al., 2010; Archbold et al., 2011).
Regardless of the precise peptide orientation in each class B
GPCR, binding to the receptor ECD helix occurs at the
approximate position of I41 of CLR, as we have proposed
for cognate peptide binding to the CGRP, AM1 and AM2
receptors.
We suggest that the binding mode of CGRP, AM and AM2
to their receptors is broadly similar to other class B GPCRs,
but that the RAMP alters the conformation of the CLR to
influence ligand affinity and thus potency. In particular, it
controls accessibility of the peptide-binding epitope on the
N-terminus of the CLR, particularly where this is itself part of
the CLR-RAMP interface. In addition, there are direct inter-
actions from two key residues positioned at 74/101 and
84/111 in the RAMPs (Figure 8). This results in a slightly
Figure 7
Effect of mutations in N-terminal CLR residues on ligand binding. (A) Competitive binding curves showing the displacement of [125I]-rAM by hAM,
hAM2 and hαCGRP at the AM1 receptor. (B) Specific binding of [125I]-rAM to selected CLR mutants at the AM1 receptor expressed as a percentage
of WT binding (100%). (C) Specific binding of [125I[-rAM to selected CLR mutants at the AM2 receptor expressed as a percentage of WT binding
(100%). (D) Competitive binding curves showing the displacement of [125I]-rAM by hAM for I52A in the AM1 receptor and Q45A in the AM2
receptor, compared with WT controls. Data were combined and data points shown are mean ± SEM of at least three individual data sets.
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Figure 8
Figure depicting the amino acid residues likely to be involved in peptide binding, generated using PyMol. (A) CGRP-binding residues in the CGRP
receptor ECD (3N7S; a representative structure for the CGRP receptor), as previously determined by alanine scanning mutagenesis (Barwell et al.,
2010). (B) AM-binding residues in the CGRP receptor. (C) AM-binding residues in the AM1 receptor ECD (3AQF). The AM1 receptor structure is
N-terminally truncated to V36; thus, many residues involved in AM binding could not be depicted. This may indicate increased mobility of this
region of the receptor ECD. (D) AM-binding residues in our AM2 receptor ECD model. RAMP1 is shown in blue, RAMP2 in yellow, RAMP3 in pale
blue and CLR in green. Residues where substitution resulted in a decrease in peptide potency are shown in red; those that cause an increase in
potency are shown in orange. In each part of the figure, (i) shows secondary structural elements with residues involved represented as sticks and
(ii) shows the surface map.
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different manner of binding for the AM, AM2 and CGRP
peptides across the three receptors. Subtle differences in CLR
ECD conformation with each RAMP could affect the function
of the receptor as a whole. This could be reflected further
downstream in terms of differential receptor signalling.
Structure-based drug design at these receptors will need to
take these factors into account.
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Figure S1 Effect of mutations in N-terminal CLR residues on
Emax values. Data are ordered to show the effect by RAMP (left)
or peptide (right). For comparisons with the CGRP receptor,
these values were calculated from the data presented in
Barwell et al. (2010). *P < 0.05; **P < 0.01; ***P < 0.001 versus
relevant WT receptor by paired t-test.
Figure S2 Amino acid sequence alignment of CLR sequences
from selected species: human (homo sapiens), chicken (Gallus
gallus), mouse (Mus musculus), rat (Rattus norvegicus), puffer-
fish CLR1 (Takifugu obscurus), salmon (Salmo salar) and pig
(Sus scrofa) showing only the ECD helix region. The align-
ment was generated using Clustal Omega, and ESPript total
conservation of residues is shown in red, partial conservation
in yellow. The sequence was aligned using the % equivalence
algorithm on the basis of physicochemical parameters.
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